Several doses of an oral polio vaccine made by a government-owned firm in India have failed quality tests.
In what is being termed a major setback to India’s polio eradication program, the Central Drugs Laboratory in Kasauli, Himachal Pradesh, declared 16 batches (30,000 vials) manufactured by Bibcol (Bharat Immunological and Biologicals Corporation Limited) as 'substandard'.
The public sector undertaking supplies vaccines to the government’s polio eradication program. Approximately 90 million doses of the polio vaccine are required for a follow-up program slated for June.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze